Anti-SARS-CoV-2 Antibody Status at the Time of Hospital Admission and the Prognosis of Patients with COVID-19: A Prospective Observational Study

Jurenka, Ján; Nagyová, Adriana; Dababseh, Mohammad; Mihalov, Peter; Stankovič, Igor; Boža, Vladimír; Kravec, Marián; Palkovič, Michal; Čaprnda, Martin; Sabaka, Peter

doi:10.3390/idr14060100

Cited by 5 publications

(8 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients who died from COVID-19, the level of CRP was about 10 times higher than in those who recovered [ 24 ]. Moreover, in severe infections, CRP levels were associated with higher anti-spike IgG antibody titers [ 23 , 24 , 25 , 26 ]. In our study, the CRP levels moderately correlated with anti-S IgG but not at all with anti-N IgG, despite the high anti-N IgG titers.…”

Section: Discussionmentioning

confidence: 99%

Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity

Desheva

Lerner²,

Shvedova³

et al. 2023

Antibodies

View full text Add to dashboard Cite

In this retrospective cohort study, we investigated the formation of individual classes of antibodies to SARS-CoV-2 in archived serial sera from hospitalized patients with the medium–severe (n = 17) and severe COVID-19 (n = 11). The serum/plasma samples were studied for the presence of IgG, IgM and IgA antibodies to the recombinant S- and N-proteins of SARS-CoV-2. By the 7th day of hospitalization, an IgG increase was observed in patients both with a positive PCR test and without PCR confirmation of SARS-CoV-2 infection. Significant increases in the anti-spike IgG levels were noted only in moderate COVID-19. The four-fold increase of IgM to N-protein was obtained more often in the groups with mild and moderate infections. The IgA levels decreased during the infection to both the S- and N-proteins, and the most pronounced decrease was in the severe COVID-19 patients. The serum IgG to S-protein one week after hospitalization demonstrated a high-power relationship (rs = 0.75) with the level of RBD antibodies. There was a medium strength relationship between the levels of CRP and IgG (rs = 0.43). Thus, in patients with acute COVID-19, an increase in antibodies can develop as early as 1 week of hospital stay. The SARS-CoV-2 antibody conversions may confirm SARS-CoV-2 infection in PCR-negative patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity

Desheva

Lerner²,

Shvedova³

et al. 2023

Antibodies

View full text Add to dashboard Cite

show abstract

“…It is noteworthy that studies correlating more severe disease to more vigorous antibody response in COVID-19, are performed using laboratory tests, and not LFIAs, to assess the antibody titer [90] . Recently Jurenka and co-workers using a LFIA kit assessed anti-S SARS-CoV-2 antibodies in hospitalized patients and found that the absence of IgM and IgG at the time of admission predicted in-hospital mortality [91] . However, results from this study are in sharp contrast with previous findings [68] .…”

Section: Performance and Reliability Of Lfia In Post-infectionmentioning

confidence: 99%

“…A large number of studies evaluated the accuracy of LFIA for antibody detection compared to ELISA, CLIA or RT-PCR and some meta-analyses and reviews have summarized results of these studies [11] , [84] , [86] , [91] – [95] . Deeks and colleagues in an early Cochrane review, including sparse data collected in various time ranges from the disease onset, found inconsistencies between the available assays, however, POCs had higher pooled sensitivity than ELISA for IgG and IgG-IgM [86] .…”

Section: Performance and Reliability Of Lfia In Post-infectionmentioning

confidence: 99%

“…Successively, other meta-analyses have confirmed the discrepancies between the tests, reporting a low pooled sensitivity and a high specificity of LFIA for both IgG and IgM [26] , [84] , [92] – [95] . Vengesai and co-workers evaluated the accuracy of different serological tests for IgG (17 studies) IgM (16 studies) and IgG-IgM (27 studies) and found that overall the most sensitive test for IgG was CLIA, whereas ELISA had the highest diagnostic accuracy for combined IgG-IgM [91] . The largest meta-analysis performed on LFIA by Gracienta et al included 33 studies and showed that the combined detection of IgM and IgG had the highest sensitivity and NPV of 93%, whereas the single IgG detection method had the highest specificity and PPV of 96.68% [95] .…”

Section: Performance and Reliability Of Lfia In Post-infectionmentioning

confidence: 99%

See 1 more Smart Citation

An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies

Spicuzza¹,

Campagna²,

Maria³

et al. 2023

AIMSMICRO

View full text Add to dashboard Cite

<abstract> <p>Over the last three years, after the outbreak of the COVID-19 pandemic, an unprecedented number of novel diagnostic tests have been developed. Assays to evaluate the immune response to SARS-CoV-2 have been widely considered as part of the control strategy. The lateral flow immunoassay (LFIA), to detect both IgM and IgG against SARS-CoV-2, has been widely studied as a point-of-care (POC) test. Compared to laboratory tests, LFIAs are faster, cheaper and user-friendly, thus available also in areas with low economic resources. Soon after the onset of the pandemic, numerous kits for rapid antibody detection were put on the market with an emergency use authorization. However, since then, scientists have tried to better define the accuracy of these tests and their usefulness in different contexts. In fact, while during the first phase of the pandemic LFIAs for antibody detection were auxiliary to molecular tests for the diagnosis of COVID-19, successively these tests became a tool of seroprevalence surveillance to address infection control policies. When in 2021 a massive vaccination campaign was implemented worldwide, the interest in LFIA reemerged due to the need to establish the extent and the longevity of immunization in the vaccinated population and to establish priorities to guide health policies in low-income countries with limited access to vaccines. Here, we summarize the accuracy, the advantages and limits of LFIAs as POC tests for antibody detection, highlighting the efforts that have been made to improve this technology over the last few years.</p> </abstract>

show abstract

“…The delayed dynamics of the antibody response to SARS-CoV-2 have been identified as a predictor of poor outcomes, possibly impairing the ability to fully recover from the disease. An association between delayed antibody response and disease severity and the extent of organ damage has been proposed [12,13]. The impact of delayed antibody response on QoL in COVID- 19 survivors is yet to be determined.…”

Section: Introductionmentioning

confidence: 99%

Delayed Antibody Response in the Acute Phase of Infection Is Associated with a Lower Mental Component of Quality of Life in Survivors of Severe and Critical COVID-19

Dababseh,

Sabaka,

Duraníková

et al. 2024

JCM

Self Cite

View full text Add to dashboard Cite

Background: The long-term sequelae of coronavirus disease 2019 (COVID-19) significantly affects quality of life (QoL) in disease survivors. Delayed development of the adaptive immune response is associated with more severe disease and a worse prognosis in COVID-19. The effects of delayed immune response on COVID-19 sequelae and QoL are unknown. Methods: We conducted a prospective study to assess the relationship between the delayed antibody response in the acute phase of infection in naïve unvaccinated patients suffering from severe or critical COVID-19 and their QoL 12 months after hospital discharge. The 12-item Short Form Survey (SF-12) questionnaire was used for assessment of QoL. The SF-12 evaluates both mental and physical components of QoL, incorporating a mental component score (MCS-12) and a physical component score (PCS-12). A delayed antibody response was defined as testing negative for anti-spike SARS-CoV-2 antibodies at the time of hospital admission. Results: The study included 274 patients (154 men and 120 women). Of the enrolled patients, 144 had a delayed immune response. These patients had a significantly lower MCS-12 (p = 0.002), but PCS-12 (p = 0.397) was not significantly different at the 12-month follow-up compared to patients with positive anti-spike SARS-CoV-2 antibodies. The MCS-12 at the time of follow-up was negatively associated with delayed antibody response irrespective of possible confounders (p = 0.006; B = 3.609; ηp2 = 0.035; 95% CI = 1.069–6.150). An MSC-12 below 50 points at the time of follow-up was positively associated with delayed antibody response (p = 0.001; B = 1.092; OR = 2.979; 95% CI = 1.554–5.711). Conclusions: This study confirmed that, in patients with severe and critical COVID-19, a negative result for anti-spike SARS-CoV-2 antibodies at the time of hospital admission is associated with a lower mental component of QoL in unvaccinated patients naïve to COVID-19 one year after hospital discharge.

show abstract

Anti-SARS-CoV-2 Antibody Status at the Time of Hospital Admission and the Prognosis of Patients with COVID-19: A Prospective Observational Study

Cited by 5 publications

References 32 publications

Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity

Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity

An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies

Delayed Antibody Response in the Acute Phase of Infection Is Associated with a Lower Mental Component of Quality of Life in Survivors of Severe and Critical COVID-19

Contact Info

Product

Resources

About